Jan Hinrichs

IR

[CVIR Endovascular @cvirendo]

#sundayread

This paper explores portal Vein Recanalization–Transjugular Intrahepatic Portosystemic Shunt (PVR-TIPS) with superior mesenteric vein access and balloon-assisted shunt placement

https://t.co/Y7F6haF2ya

#irad #interventionalradiology

[CIRSE @cirsesociety]

@cvironco, the first journal dedicated to advancing the field of IO and related fields in cancer care and patient management, opened for submission today. EIC Prof. Thomas Helmberger spoke to us on the background of the new journal.👉 https://t.co/kHo3D6r5I2

#CVIRoncology #IRad

[Arndt Vogel @ArndtVogel]

🔥Hot off the press:
ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer
@ESMO_Open
https://t.co/e3zL5gE7kN
👉get the lastest update on the management of biliary tract cancer
@myESMO @EASLedu @ILCAnews @curecc #livertwitter

[CVIR Endovascular @cvirendo]

Read the review of the literature and pictorial essay on benefits and advances of Cone Beam CT use in prostatic artery embolization

https://t.co/BcYID4nyWX

#irad #interventionalradiology

[Arndt Vogel @ArndtVogel]

Comparison of 1st chemotherapy in unresectable locally advanced or metastatic #PDAC
@TheLancetOncol
https://t.co/gRKDiQRWy9
🔎systematic review & Bayesian network meta-analysis, 79 trials, 22 168 pts
👉NALIRIFOX & FOLFIRINOX may be the preferred options if feasible
@myESMO

[Lea Alhilali, MD @teachplaygrub]

Talk about bad to the bone!

Aneurysms are common—but do you know which are the bad actors at risk for rupture?

This month's @the_ajnr SCANtastic shows you which aneurysms are bursting with risk!

https://t.co/lM5lk81f7h

Just remember the 4 B’s for BAD:

1. BIG
--Larger aneurysm = more likely to rupture
--Aneurysms > 7mm more likely to rupture
--Remember this b/c rolling a lucky 7 in Vegas makes you rupture w/excitement

2. BACK
--Aneurysms in the back are more likely to rupture
--PCOMM & post circ aneurysms are more likely to rupture

3. BLEB
--Aneurysms w/ “daughter” aneurysms or blebs are more likely to rupture
--Increases risk by 50%

4. BALLOONING
--Growing or ballooning aneurysm = increased risk of rupture
--Any growth by >1 mm in any diameter, increases the risk of rupture. Small changes do matter!

In this month’s @the_ajnr, Van Tuijl et al. used 4D MRA to show that these high-risk imaging findings are merely surrogate markers for low wall shear stress.

Low wall shear stress is bad bc shear stress is required to removed thrombus, plaque & inflammatory cells that weaken the aneurysm wall

So now hopefully your mind is bursting w/new things to look for w/aneurysms!

Check out the article for yourself: https://t.co/lM5lk81f7h

[Lea Alhilali, MD @teachplaygrub]

1/Time to rupture all your misconceptions about aneurysms!

When you see an aneurysm on imaging, do you know if it’s at high risk of rupture?

This month’s @theAJNR SCANtastic shows you which aneurysms are bursting w/risk!

https://t.co/pHRcoYh3ln

[Lea Alhilali, MD @teachplaygrub]

1/Raise your hand if you’re confused by the BRACHIAL PLEXUS!

I could never seem to remember or understand it—but now I do & I’ll show you how!

A thread so you will never fear brachial plexus anatomy again!

[Oren Gottfried, MD @OGdukeneurosurg]

Coronaries

[Arndt Vogel @ArndtVogel]

🔥off the press:
Tislelizumab versus Sorafenib in 1st line treatment of HCC: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Liver Cancer
https://t.co/H9b53844Ep
👉ICI monotherapy is a not to missed option in HCC, specifically for frail pts
@EASLnews @myESMO @ILCAnews #livertwitter

[Lea Alhilali, MD @teachplaygrub]

1/Do radiologists sound like they are speaking a different language when they talk about MRI?

T1 shortening what? T2 prolongation who?

Here’s a translation w/an introductory thread to MRI.

[Seminars in Interventional Radiology @SemInterventRad]

This article is a brief review of indications and technical parameters of PAE as well as commonly debated topics throughout the literature.
https://t.co/GlbCpGkBWB
#irad #radtwitter #radiology #MedTwitter

[Journal of Hepatology @JHepatology]

Immunotherapy for hepatocellular carcinoma

➡️The next evolution in expanding access to liver transplantation

Full text here👉https://t.co/2Uj9hYWhA0

@MichaelLiMD
@SherrieBhoori
#LiverTwitter

[Arndt Vogel @ArndtVogel]

🔥off the press
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC
@JHEP_Reports
🔎🗺️RWD study
❓how to best select for TACE > AFP & Tumor burden
🧐helpful for the discussion in the tumor board
👇my author link:
https://t.co/c6ECELXhvQ
@myESMO @EASLedu @ILCAnews #livertwitter

[Seminars in Interventional Radiology @SemInterventRad]

Explore recent advancements in embolic materials for GAE, highlighting their properties and potential benefits.
https://t.co/S3em5K9OsC

#irad #radtwitter #radiology #MedTwitter

[Angela Lamarca @DrAngelaLamarca]

MO in #HCC at #ESMO24 (2/2)

5-year OS data from HIMALAYA with DurvaTreme

19.6% vs 9.4% OS rate at 5-years!
Larger differences if disease control or response was achieved

#Long-term #survivors are a reality in #HCC 😊

@myESMO #ESMOAmbassadors @GrupoTTD @EASLnews

[Angela Lamarca @DrAngelaLamarca]

New data for #intermediate #HCC at #ESMO24 from LEAP-012 trial

👍🏻PFS/ORR benefit for LenvaPembro+TACE (vs TACE)
🤞🏻OS promising
🤝Toxicity acceptable

👉Systemic+TACE as SOC may be close to be a reality!! (2nd +ve study 😉 EMERALD-1)

@myESMO #ESMOAmbassadors @GrupoTTD @EASLnews

[Arndt Vogel @ArndtVogel]

Clinical Outcomes and Histologic Findings of pts With HCC With Durable Partial Response or Durable Stable Disease After Atezolizumab + Bevacizumab
@JCO_ASCO
https://t.co/OUGrI2EDjA
🔎Imbrave150 & RWD
👉favorable PFS & OS + high rates of pCR in pts w/ PR for ≥6 mo
@myESMO @EASLnews @ILCAnews #livertwitter

[Arndt Vogel @ArndtVogel]

ITT outcomes of pts with HCC receiving immunotherapy before liver transplant
@JHepatology
https://t.co/n8kWr4FUca
🔎🇺🇸VITALITY study
👉86 pts
👉75.6% downstaged
👉36% LTx
👉3-year ITT OS 71.1%
👉 7 rejections, 1 graft lost
🧐More evidence to support ICI before LTx
@myESMO @EASLnews @ILCAnews #livertwitter

[Arndt Vogel @ArndtVogel]

Iparomlimab & tuvonralimab with beva and/or CTx in 1L HCC
#ESMO24
🔎Phs II/III DUBHE-H-308
👉QL1706/bev/XELOX: ORR 35%. DCR: 87%
👉QL1706/bev: ORR 36%, DCR 8ß%
🧐revival of CTx in HCC? Signal strong enough for planned Phs 3 w/ QL1706/bev/XELOX?
@myESMO #ESMOAmbassadors @EASLedu